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Background: Crosstalk between malignant hepatocytes and the surrounding peritumoral stroma is a key
modulator of hepatocarcinogenesis and therapeutic resistance. To examine the chemotherapy resistance of these
two cellular compartments in vitro, we evaluated a well-established hepatic tumor cell line, HepG2, and an adult
hepatic stellate cell line, LX2. The aim was to compare the chemosensitization potential of arsenic trioxide (ATO) in
combination with sorafenib or fluorouracil (5-FU), in both hepatic tumor cells and stromal cells.
Methods: Cytotoxicity of ATO, 5-FU, and sorafenib, alone and in combination against HepG2 cells and LX2 cells
was measured by an automated high throughput cell-based proliferation assay. Changes in survival and apoptotic
signaling pathways were analyzed by flow cytometry and western blot. Gene expression of the 5-FU metabolic
enzyme, thymidylate synthase, was analyzed by real time PCR.
Results: Both HepG2 and LX2 cell lines were susceptible to single agent sorafenib and ATO at 24 hr (ATO IC50: 5.3
μM in LX2; 32.7 μM in HepG2; Sorafenib IC50: 11.8 μM in LX2; 9.9 μM in HepG2). In contrast, 5-FU cytotoxicity
required higher concentrations and prolonged (48–72 hr) drug exposure. Concurrent ATO and 5-FU treatment of
HepG2 cells was synergistic, leading to increased cytotoxicity due in part to modulation of thymidylate synthase
levels by ATO. Concurrent ATO and sorafenib treatment showed a trend towards increased HepG2 cytotoxicity,
possibly due to a significant decrease in MAPK activation in comparison to treatment with ATO alone.
Conclusions: ATO differentially sensitizes hepatic tumor cells and adult hepatic stellate cells to 5-FU and sorafenib.
Given the importance of both of these cell types in hepatocarcinogenesis, these data have implications for the
rational development of anti-cancer therapy combinations for the treatment of hepatocellular carcinoma (HCC).
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StromaBackground
Recent data has demonstrated that the crosstalk between
malignant hepatocytes and non-parenchymal, stromal
liver cells, or the hepatic stellate cells, is crucial to hepa-
tocarcinogenesis [1]. In vitro hepatic stellate cells within
the tumor microenvironment promote hepatocarcinoma
cell growth, epithelial to mesenchymal transition (EMT),* Correspondence: gayathri.devi@duke.edu
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reproduction in any medium, provided the orand tumor invasion [2-4]. In vivo, subcutaneous co-
implantation of hepatic stellate cells and hepatocellular
carcinoma cells into nude mice results in significantly
increased tumor growth and tumor volumes in compari-
son to the implantation of hepatocellular carcinoma cells
alone [5]. These studies highlight tumor-stroma interac-
tions as a potential mediator of chemoresistance.
Arsenic trioxide (ATO), used for the treatment of
relapsed acute promyelocytic leukemia, activates the cas-
pase cascade and induces production of reactive oxygen
species, resulting in apoptosis [6]. Multiple groups initially
demonstrated that treatment of HCC cell lines with ATOral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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concentration-dependent manner [7-9]. Furthermore,
both in a rat model of diethaylnitrosamine-induced HCC
and in murine HCC xenografts, ATO treatment signifi-
cantly increased rates of apoptosis in tumor nodules in
comparison to vehicle control [10,11]. Unfortunately, in a
phase II clinical trial, single agent ATO did not show ac-
tivity against advanced hepatocellular carcinoma (HCC)
[12]. Possible explanations for the discrepant results be-
tween the preclinical data and the clinical data include
HCC tumor heterogeneity both in humans and model sys-
tems. In addition, the preclinical model systems assessed
cytotoxicity of ATO on the tumor compartment, but not
on the supporting stromal compartment.
The pro-apoptotic effect of ATO can enhance the effi-
cacy of other drugs given in combination as has been
noted in other tumor types. In colorectal adenocarcin-
oma cells, ATO acts as a chemosensitizer to the pyrimi-
dine antimetabolite 5-fluorouracil (5-FU) [13]. 5-FU, an
inhibitor of thymidylate synthase (TS), was one of the
first reported chemotherapeutic agents tested in the
treatment of HCC with response rates of approximately
10% [14]. Capecitabine, an orally administered 5-FU pro-
drug, yielded response rates of 11% in patients with
advanced HCC [15]. In addition to the benefit provided
by this modest response rate, the fluoropyrimidines have
a distinct advantage in the treatment of hepatobiliary
malignancies in that they exhibit a favorable safety pro-
file and do not require a priori dose reduction secondary
to liver dysfunction [16,17].
Based on these data we were interested in compar-
ing the chemosensitivity of the hepatic tumor com-
partment and the hepatic stromal compartment to
single agent ATO, 5-FU and sorafenib. In the present
study, the tumor compartment was modeled using a
human, well-differentiated, epithelial hepatic tumor
line, HepG2 [18], and the stromal compartment was
modeled using the human hepatic stellate cell line,
LX2 [19-21]. We hypothesized that the ATO/5-FU
combination and the ATO/sorafenib combination
would result in potentiation of apoptosis in the tumor
and stromal cell line.
Methods
Cell culture
HepG2 (ATCC) cells and LX2 cells [21] were cultured as
previously described [18,19]. Cells at 50% confluence in a
96-well plate (Corning Incorporated, Corning, NY, USA)
were treated with increasing concentrations of arsenic
trioxide (Cephalon, Philadelphia, PA), 5-fluorouracil
(APP pharmaceuticals, Schaumburg, IL), or sorafenib
(Bayer Healthcare Pharmaceuticals and Onyx Pharma-
ceuticals, San Francisco, CA) in serum-containing
medium for the time periods indicated.Automated cell proliferation assay
HepG2 and LX2 cells were plated at 4000 and 3000
cells/well respectively in 96-well clear tissue culture
plates (Costar, Corning Incorporated, Corning, NY) in
200 μl media and allowed to adhere overnight. Media
was then removed from the cell plates and drug (200
μL) was transferred from intermediate plates to the cell
plates using a Biomek NX workstation (Beckman
Coulter Inc., Fullerton, CA) equipped with a 96-well
head. For intermediate drug plates, using a Biomek 3000
workstation, drugs were serially diluted (eight concentra-
tions) in media in 96-well 1.1 ml deep well plates (Axy-
gen, VWR). For combination studies, the serial dilution
was carried out at a 2-fold higher concentration and
then a fixed concentration of a second drug added to all
wells of the dose response intermediate plate. Each plate
consisted of the following controls: column 1 contained
media (no cells), columns 2 and 11 cells plus DMSO
(final concentration 0.5%), and column 12 cells plus
media. For combination experiments, column 11 would
contain cells plus the second compound only. Cells were
incubated with drugs for 24 hr, 48 hr, 72 hr and 96 hr
and then cell proliferation assessed by an automated
MTT assay adapted from our previous manual proced-
ure [22]. Prior to preparation of cells for the MTT assay,
all wells were viewed under an inverted scope to assess
for the general number of attached cells in order to con-
firm correlation with assay values. Briefly, using the Bio-
mek NX equipped with a 96-well head for all steps, MTT
(40 μL) was added to the cell plates and incubated for
2 h. Media was then removed, DMSO (100 μL) added
and the plates read at 550 nm in a SpectraMax Plus plate
reader (Molecular Devices, Sunnyvale, CA, USA).
Western blot analysis
Cells were treated as noted above and lysates were
prepared. Western blot analysis was performed as previ-
ously described [22]. Membranes were incubated with
primary antibodies against XIAP (1:2000; BD Bio-
science), actin (1:1000; Santa Cruz Biotechnology),
procaspase-9 (1:2000; NeoMarkers), and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; 1:2000; Santa
Cruz Biotechnology) for 1 h at room temperature. Mem-
branes were incubated with primary antibodies against
survivin (1:12000; R&D BioSystems), p-MAPK (1:1000;
Cell
Signaling), MAPK (1:1000; Cell Signaling), p-JNK
(1:1000; Cell Signaling), and JNK (1:1000; Cell Signaling)
overnight at 4°C.
Drug synergism analysis
Analysis of drug synergism was performed using the
Calcusyn software (Biosoft, Cambridge, UK), which
uses the Chou-Talalay method [23] and generates
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(CI) is a quantitative measurement of the relationship
between two agents; a CI greater than 1 indicates an-
tagonism, while a CI of one indicates an additive inter-
action and a CI less than one indicates synergism.
Cell cycle analysis
Cells were treated with DMSO or arsenic trioxide (5 μM
or 25 μM) for 24 hr and then stained with propidium
iodide (PI) as previously reported [24]. At least 25,000
events were collected on a FACScalibur flow cytometer
(Becton Dickinson) and analyzed using the Cellquest
software (Becton Dickinson). Data presented represents
n = 2 replicates.
Quantitative real-time PCR for thymidylate synthase
HepG2 cells were seeded at 300,000 cells per well in clear,
6-well Costar plates and allowed to attach overnight. After
treatment with vehicle (DMSO), 0.5 μM ATO, 5 μM ATO,
or 25 μM ATO for 24 hrs, media was discarded and RNA
extracted from the cells using the RNA extraction kit
(Ambion, Austin, TX, USA) as previously described
[25]. RNA (0.4 μg) was converted into cDNA using
the High Capacity cDNA RT-PCR kit (Applied Bio-
systems, Carlsbad, CA, USA). Quantitative real-time
PCR analyses were performed using primers fromA


































Figure 1 ATO inhibits HepG2 and LX2 Cell Proliferation. HepG2 (A) an
for 24 hrs, 48 hrs, 72 hrs and 96 hrs (HepG2 only) and cell proliferation asse
were calculated and data normalized to vehicle control. Relative IC50 value
regression in GraphPad Prism (n = 3 replicates).Integrated DNA Technologies. Amplification reactions
were carried out in an ABI Prism Fast 7500 system (Ap-
plied Biosystems Inc, Foster City, CA). Gene expression for
thymidylate synthase (TS) was performed using the follow-
ing primer sets from Integrated DNA Technologies: TS
forward 50-GGCCTCGGTGTGCCTTT-30, reverse 50-
GATGTGCGCAATCATGTACGT-30. Power SYBR Green
PCR Master Mix (Applied Biosystems) was used for the
PCR to a final volume of 20 μL. A β-actin primer set
(Ambion) was used as an internal control. Cycling condi-
tions were 50°C for 2 minutes and 95°C for 10 mins and
followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min.
The standard curve method was used to obtain threshold
values (CT). Triplicate CT values were analyzed in Microsoft
Excel using the comparative CT method as described by the
manufacturer (Applied Biosystems). Fold differences were
calculated as described previously [22] and represent
changes normalized to a vehicle reference.Statistical analysis
GraphPad Prism 5 (GraphPad Software, San Diego, CA) was
used for nonlinear regression statistical analysis. For each
concentration, percent inhibition values were calculated and
IC50 values determined using a four-parameter dose–re-
sponse (variable slope) equation in GraphPad Prism.B
































d LX2 (B) cells were treated with ATO at the indicated concentrations
ssed by MTT assay. For each concentration, percent inhibition values
s shown in the corresponding tables were determined by non-linear
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HepG2 and LX2 cells are sensitive to the cytotoxic effects
of arsenic trioxide
In order to evaluate the effect of single agent ATO on
cellular proliferation, HepG2 and LX2 cells were treated
with increasing concentrations of drug for 24 to 96 hr.
Dose response curves demonstrate the sensitivity of both
cell lines in a time-dependent fashion, with LX2 cells
being more sensitive to ATO treatment with a relative
IC50 of 5.3 μM at 24 hrs of treatment compared to a
relative IC50 of 32.7 μM for the HepG2 cells at the same
incubation time (Figures 1A and 1B). In order to exam-
ine the mechanism of ATO-induced cytotoxicity, cell
cycle analysis was performed on HepG2 and LX2 cells
treated with 5 μM or 25 μM of ATO for 24 hr. Flow
cytometry of the LX2 cells demonstrates an early apop-
totic population, as represented by the presence of a
sub-G1 peak, in cells treated with 5 μM and 25 μM
ATO (Figure 2) in comparison to vehicle control. 50 μM
ATO treatment is required to induce apoptosis of the
HepG2 cells thus confirming the findings of our cytotox-
icity assays (data not shown). Taken together, these data
indicate that the hepatic stellate cells are more sensitive




Figure 2 ATO induces apoptosis of LX2 cells. HepG2 and LX2 cells were
24 hrs. Apoptotic cells were determined by propidium iodide staining and
represents an early apoptotic cell population. A representative example ofSynergistic cytotoxicity of arsenic trioxide in combination
with fluorouracil in HepG2 cells
To reduce variability and facilitate multiple cell line and
drug combinations, dose response and drug combination
experiments were carried out in 96-well plate format
using an automated, high throughput system. First, to
determine the degree of cytotoxicity of 5-FU alone on
the LX2 and HepG2 cells, both cell lines were treated
with increasing concentrations of 5-FU for 24 and 72 hr.
Neither cell type experienced significant cytotoxicity fol-
lowing 24 hr of treatment, but cytotoxicity was observed
in HepG2 cells treated with 5-FU for 72 hr (IC50 of
5 mg/ml at 72 hr) (Figure 3A). In contrast, LX2 cells re-
main resistant to 5-FU even with high drug concentra-
tions and prolonged exposure (Figure 3B).
To assess potential synergy between 5-FU and ATO,
HepG2 and LX2 cells were treated for 24 hrs with in-
creasing concentrations of 5-FU in the absence or pres-
ence of a fixed concentration of ATO. At 24 hrs 5-FU
has minimal effect on cell proliferation of HepG2
(Figure 4A, left panel) or LX2 cells (Figure 4B, left
panel). ATO treatment (5 μM) alone of HepG2 cells for
24 hr also results in minimal cell death, but in combin-
ation with 5 mg/ml 5-FU, there is a significant decrease
in cell proliferation with the combination treatment (p ATO 25 µM ATO
untreated or incubated in the presence of 5 μM or 25 μM ATO for
FACS analysis. The red arrow indicates the sub –G1 peak which






































































Figure 3 5-FU inhibits HepG2 and LX2 Cell Proliferation at 72 hrs. HepG2 (A) and LX2 (B) cells were treated with 5-FU at the indicated
concentrations for 24 and 72 hrs and cell proliferation was assessed by MTT assay. For each concentration, percent inhibition values were
calculated and data normalized to vehicle control. IC50 values shown in the corresponding tables were determined by non-linear regression in
GraphPad Prism (n= 3 replicates).
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cells treated with the combination of 5-FU and ATO
demonstrated no additional cytotoxicity over that which
was seen with ATO treatment alone (Figure 4B, right
panel). We have tested ATO at both 5 and 10 μM con-
centrations for LX2 cells. As the inhibition curve for
ATO treatment of LX2 cells at 24 h (Figure 1B) plat-
eaued well above 0% at ~40% it is difficult to summarize
such a curve in a single value as there are effects on
both potency and efficacy. Hence, we chose to test both
the calculated IC50 concentration (relative IC50 value of
5 μM) and the concentration that reduced proliferation
by 50% (absolute IC50 value of 10 μM). LX2 cells treated
with the combination of 5-FU and ATO at either con-
centration (10 μM data shown in Figure 4A left panel
and both 5 and 10 μM shown in Figure 4A, right panel)
demonstrated no additional cytotoxicity over that which
was seen with ATO treatments alone.
To further characterize the interaction between 5-FU
and ATO, the dose-effect curves were analyzed using
Calcusyn software. The combination index (CI) for the
interaction between ATO (5 μM) and 5-FU (increasing
dose) in HepG2 cells was calculated to be 0.098-0.159
(Figure 4C), which is indicative of strong synergism in
this cell model. To assess the effect of ATO and 5-FU
treatment on apoptosis, expression of procaspase-9, the
inactive form of the apoptotic effector caspase-9, and X-
linked inhibitor of apoptosis protein (XIAP), the most
potent mammalian caspase-inhibitor, was examined inHepG2 and LX2 cell lysates. Data in Figure 4D show
that procaspase 9 and XIAP decrease in cells undergo-
ing death at lower concentration with ATO in LX2
cells compared to HepG2 cells consistent with
enhanced potency of ATO in LX2 cells. Procaspase-9
expression was preserved in HepG2 cells treated with
5 mg/ml 5-FU or 20 μM ATO alone. 5-FU as a single
agent at 5 mg/ml did not cause any decrease in pro-
caspase 9 or XIAP in either cell lines. However, ex-
pression was abolished when cells were treated with
5 mg/ml 5-FU and 5 μM ATO in combination
(Figure 4D), suggesting enhanced activation of apop-
tosis by this combination in HepG2.ATO inhibits thymidylate synthase expression in a dose
dependent fashion
An earlier study in colorectal adenocarcinoma cells has
shown that a combination of ATO and 5-FU results in
enhanced cytotoxicity due in part to ATO-induced in-
hibition of thymidylate synthase (TS) [13]. To evaluate
the effect of ATO on TS expression in HepG2 cells, cells
were treated with DMSO control, 0.5 μM ATO, 5 μM
ATO or 25 μM ATO for 24 hours. Quantitative real-
time PCR analysis demonstrated that there was a dose
dependent reduction in TS expression (Figure 5). ATO-
induced modulation of TS levels may, in part, account
for the enhanced apoptosis with the 5-FU combination
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p < 0.0001 
Figure 4 (See legend on next page.)
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Figure 4 Combination of ATO with 5-FU in HepG2 and LX2 cell lines. HepG2 cells (A) were treated with increasing concentrations of 5-FU in
the absence or presence of ATO (5 μM) for 24 hrs (left panel). The bar graph (right panel) demonstrates relative proliferation values for HepG2
cells when treated with 5 mg/ml 5-FU alone, 5 μM ATO alone and the combination of 5 mg/ml 5-FU and 5 μM ATO (p value < 0.0001). (B) LX2
cells were treated with increasing concentrations of 5-FU in the absence or presence of ATO (10 μM) for 24 hrs (left panel). The bar graph (right
panel) demonstrates relative proliferation values for LX2 cells when treated with 5 mg/ml 5-FU alone, 5 μM, 10 μM ATO alone and the
combination of 5 mg/ml 5-FU+ 5 μM or 10 μM ATO. For each concentration, percent inhibition values were calculated and data normalized to
vehicle control and represented as n = 3 replicates+/− SEM. (C) Dose effect curve for ATO and 5-FU combination in HepG2 cells was generated
using Calcusyn software. (D) HepG2 treated cell lysates (vehicle, 20 μM, 50 μM or 75 μM ATO, 5 mg/ml 5-FU or 5 μM ATO+ 5 mg/ml 5-FU) and
LX2 treated cell lysates (vehicle, 10 μM, 20 μM or 50 μM ATO, 5 mg/ml 5-FU or 10 μM ATO+ 5 mg/ml 5-FU) assessed for procaspase-9 and XIAP
expression by western blot analysis. GAPDH was utilized as a loading control.
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activation of MAPK and JNK
In order to query the mechanism of HepG2 resistance to
ATO, we examined the status of two cell survival path-
ways, the mitogen-activated protein kinases, ERK1 and
ERK2, and Janus-associated kinase (JNK), in ATO-treated
cells. Treatment of HepG2 cells at concentrations of ATO
that induce cell death at 24 hr resulted in robust activation
of the mitogen-activated protein kinases, (pERK1 and
pERK2, Figure 6A) and (pJNK, Figure 6B) which was not
observed in ATO-treated LX2 cells (pERK1 and pERK2,
Figure 6A) and (pJNK, Figure 6B).Combination treatment with arsenic trioxide and
sorafenib shows a trend towards increased cytotoxicity
and attenuates p-MAPK
The induction of a delayed and sustained survival signal
as seen by pERK and pJNK activation in HepG2 cells
(Figure 6) may potentially contribute to an ATO resist-
ance mechanism. Based on observations in other sys-
tems that combination treatment with ERK or JNK
inhibitors restores chemosensitivity, we hypothesized
that treatment with ATO and the multikinase inhibitor,
sorafenib, would be more efficacious than either agent
alone. In order to evaluate the effect of sorafenib on cel-
lular proliferation, HepG2 and LX2 cells were treated
with increasing concentrations of drug for 24 to 96 hr.
Sorafenib has significant cytotoxic effects on both
HepG2 and LX2 cells in a dose and time dependent
fashion (24 hr; HepG2 IC50 9.9 μM, LX2 IC50 11.8 μM;
Figure 7A and 7B). To assess synergism of the two
agents, HepG2 and LX2 cells were treated with 2.5 μM
ATO in the presence of increasing concentrations of sor-
afenib for 24 hr (Figure 7C and 7D). At 24 hr there was
no significant difference in IC50 values for the combin-
ation in comparison to sorafenib alone in both the
HepG2 and LX2 cells. However at the later time points
of 48 and 72 hr, the percent of proliferating HepG2 cells
was less for 20 μM sorafenib + 2.5 μM ATO than for 20
μM sorafenib alone (at 48 hr 13.7% versus 31%, p < 0.05;
data not shown). The increased cytotoxicity wasaccompanied by a decrease in phospho-MAPK levels in
HepG2 cells treated with ATO and sorafenib in com-
parison to ATO alone (Figure 7E). ATO treatment of
LX2 cells results in potent cytotoxicity and the addition
of sorafenib resulted in no further additive effect.Discussion and conclusions
ATO has demonstrated promising single agent activity
in both in vitro and in vivo models of HCC, but as a sin-
gle agent, has had limited activity in HCC clinical trials.
However, its ability to induce apoptosis supported the
objective of this study, which was to identify agents that
demonstrate synergy with ATO in HCC. We were inter-
ested in studying the effect of these combinations on the
tumor epithelial cells and stromal cells as a growing
body of literature highlights the cross-talk between ma-
lignant hepatocytes and the surrounding peri-tumoral
stroma as a key modulator of hepatocarcinogenesis and
chemoresistance [1].
One of the major strengths of our work is the simul-
taneous assessment of cytotoxicity on a malignant hep-
atic cell line, HepG2 cells, and a hepatic stellate cell line,
LX2 cells. In healthy livers, quiescent hepatic stellate
cells (Q-HSCs) reside in the sinusoidal space, store reti-
noids, and produce molecules that are trophic for neigh-
boring hepatocytes. In the setting of chronic liver injury,
quiescent HSCs are transformed to myofibroblastic hep-
atic stellate cells (MF-HSCs), producing the extensive
extracellular matrix that accumulates with liver fibrosis
[26,27]. As liver fibrosis is the most important determin-
ant of risk for the development of HCC, MF-HSCs are
believed to play an important role in driving tumor for-
mation. MF-HSCs infiltrate the stroma of HCCs, localiz-
ing around tumor sinusoids, fibrous septa and capsules
where they elaborate a variety of cytokines, chemokines
and growth factors [28,29]. Conditioned medium derived
from MF-HSCs has been shown to significantly induce
the proliferation and migration of malignant hepatocytes
in vitro [2]. The importance of MF-HSCs in hepatocarci-
nogenesis was recently confirmed by in vivo co-

























Figure 5 ATO inhibits thymidylate synthase expression in a
dose dependent fashion. HepG2 cells were treated for 24 hrs with
vehicle, 0.5 μM, 5 μM or 25 μM ATO. Thymidylate synthase mRNA
expression was assessed by qRT-PCR and normalized to actin levels.
Each sample was run in triplicate. A representative example of four
independent experiments is shown. Bar graph demonstrates fold
change relative to vehicle control +/− SEM.
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transplantation strongly accelerated tumor growth,
resulting in a 3-fold increase in tumor volumes as com-
pared with those generated by Ras-transformed hepato-
cytes alone [5]. Taken together, these data suggest that
in the further development of therapeutics for HCC, theU 5 20 50















Figure 6 ATO treatment of HepG2 cells results in sustained
activation of MAPK and JNK. HepG2 and LX2 cells were treated
with vehicle or 5–50 μM ATO as indicated for 24 hrs. Levels of
phosphorylated and total MAPK (A) and JNK (B) were assessed by
western blot analysis. GAPDH was utilized as a loading control.effect of compounds on both the epithelial and the stro-
mal compartment should be assessed.
Although sorafenib is FDA-approved for patients with
advanced HCC based on a modest survival benefit, there
is considerable interest in identifying more efficacious
drugs and combinations. We observed that both HepG2
cells and LX2 cells are sensitive to ATO and that treat-
ment combinations with either sorafenib or 5-FU lead to
enhanced cytotoxicity. Importantly, while HepG2 cells
are relatively resistant to 5-FU monotherapy, when com-
bined with ATO, synergy is observed as previously
demonstrated in 5-FU resistant colorectal cancer cells
[13,30]. Our data indicates that the enhanced apoptosis
associated with the combination may, in part, be
mediated by an ATO-induced, dose-depenedent de-
crease in thymidylate synthase. Subtle changes in the
level of this enzyme may affect sensitivity to 5-FU, but
certainly, other mechanisms may also place a role in the
synergy of ATO and 5-FU. Similarly, the addition of
ATO to sorafenib in HepG2 cells results in greater
cytotoxicity than either agent alone likely due to po-
tent inhibition of MAPK activation. Taken together
these results suggest that the addition of ATO leads
to the enhanced cytotoxicity of 5-FU and sorafenib.
Our data demonstrate that ATO induces apoptosis in
both the HepG2 and LX2 cell lines in a caspase
dependent fashion. These findings confirm those of
other groups, which have demonstrated that ATO
induces apoptosis of multiple solid tumor cell types [31-
34]. Furthermore, the concentrations of ATO required
for 50% cytotoxicity in our in vitro cell-based prolifera-
tion assays (5 μM) are comparable to peak levels mea-
sured in the plasma (5.5–7.3 μM) of patients undergoing
standard ATO treatment for acute promyelocytic
leukemia suggesting that these doses of ATO can be
therapeutically achieved [35]. However, it remains a pos-
sibility that higher doses of ATO will be required for op-
timal cytotoxicity in the context of HCC.
Compared to the HepG2 cells, the LX2 cells are highly
sensitive to the cytotoxic effects of single agent ATO. In
the HepG2 cells, addition of 5-FU to ATO causes a left-
ward shift in the cytotoxicity curve, revealing a potential
synergy, and importantly, the combination appears to tar-
get both the epithelial and stromal compartments. The
synergy of this combination was suggested to be due to
decrease of thymidylate synthase levels induced by ATO.
Indeed, in a phase I clinical trial of 12 patients with meta-
static, refractory colorectal cancer treated with the com-
bination of ATO and 5-FU [36], correlative studies
demonstrated that ATO caused a significant decrease in
thymidylate synthase mRNA levels in peripheral blood
mononuclear cells. Similar findings were noted in post-
treatment tumor biopsies. With the caveat of small patient




Figure 7 Treatment of HepG2 cell lines with ATO and Sorafenib results in enhanced cytotoxicity and inhibits MAPK activation. HepG2
(A) and LX2 (B) cells were treated with Sorafenib at the indicated concentrations for 24 hr, 48 hr, 72 hr and 96 hr and cell proliferation assessed
by MTT assay. For each concentration, percent inhibition values were calculated and data normalized to vehicle control. IC50 values shown in the
corresponding tables were determined by non-linear regression in GraphPad Prism. HepG2 (C) and LX2 (D) cells were treated with increasing
concentrations of Sorafenib in the absence or presence of ATO (2.5 μM) for 48 hr. Inhibition values for ATO alone (2.5 μM) are shown (◊). (E).
HepG2 cells were untreated or treated with vehicle, 2.5 μM ATO or 0.1–20 μM sorafenib +/− 2.5 μM ATO as indicated for 24 hr. Phosphorylated
and total MAPK levels were assessed by western blot analysis. GAPDH was utilized as a loading control.
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vival and overall survival. Based on these data the authors
hypothesized that ATO-induced downregulation of TS
results in resensitization of colorectal cancer to 5-FU
[13,37].In order to query the mechanism of relative HepG2 re-
sistance to ATO, we examined the status of cell survival
pathways in ATO-treated cells. Paradoxically, ATO treat-
ment of HepG2 cells at concentrations that induce cell
death resulted in robust activation of the MAPK and JNK
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in ATO-treated LX2 cells. Similar findings have been
described in multiple other cell types treated with various
pro-oxidants such as cisplatin [38] and thymoquinone
[39]. The accumulation of reactive oxygen species results
in activation of survival and proliferative signals that medi-
ate tumorigenicity and chemoresistance [39-41]. This in-
duction of a delayed and sustained survival signal by the
HepG2 cells potentially contributes to an ATO resistance
mechanism. Similar to observations in other tumor types
where combination treatment with ERK or JNK inhibitors
restores chemosensitivity [39], we demonstrate enhanced
cytotoxicity of the HepG2 cells with the ATO/sorafenib
combination in comparison to ATO alone. While studies
are needed to further clarify the exact mechanism of
cytoxicity of the ATO combinations, these data provide
strong evidence that ATO/5-FU and ATO/sorafenib dem-
onstrate enhanced cytoxicity of the epithelial and stromal
compartment. These are rational combinations to further
explore for the treatment of patients with advanced HCC.
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